High incidence of non-tuberculous mycobacteria-positive cultures among adolescent with cystic fibrosis

Cavalli, Zoé; Reynaud, Quitterie; Bricca, Romain; Nové-Josserand, Raphaële; Durupt, S.; Reix, Philippe; Perceval, M.; Montclos, Michèle Pérouse de; Lina, Gérard; Durieu, I.

doi:10.1016/j.jcf.2017.01.017

Cited by 17 publications

(25 citation statements)

References 30 publications

(64 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Changes in the porin may interrupt the drug transportation into the cell and support cell survival. Since this porin is present in fast growing mycobacteria, it would be of significance in the treatment of atypical pathogenic mycobacteria including M. abscessus studied here [30].…”

Section: Discussionmentioning

confidence: 99%

Mechanism and resistance for antimycobacterial activity of a fluoroquinophenoxazine compound

Garcia

Annamalai

Wang

et al. 2018

Preprint

View full text Add to dashboard Cite

24We have previously reported the inhibition of bacterial topoisomerase I activity by a 25 fluoroquinophenoxazine compound (FP-11g) with a 6-bipiperidinyl lipophilic side chain that 26 exhibited promising antituberculosis activity (MIC = 2.5 µM against Mycobacterium 27 tuberculosis, SI = 9.8). Here, we found that the compound is bactericidal towards 28Mycobacterium smegmatis, resulting in greater than 5 Log10 reduction in colony-forming units 29[cfu]/mL following a 10 h incubation at 1.25 µM (4X MIC) concentration. Growth inhibition 30 (MIC = 50 µM) and reduction in cfu could also be observed against a clinical isolate of 31 Mycobacterium abscessus. Stepwise isolation of resistant mutants of M. smegmatis was 32 conducted to explore the mechanism of resistance. Mutations in the resistant isolates were 33 identified by direct comparison of whole-genome sequencing data from mutant and wild-type 34 isolates. These include mutations in genes likely to affect the entry and retention of the 35 compound. FP-11g inhibits Mtb topoisomerase I and Mtb gyrase with IC50 of 0.24 and 31.5 µM, 36 respectively. Biophysical analysis showed that FP-11g binds DNA as an intercalator but the IC50 37 for inhibition of Mtb topoisomerase I activity is >10 fold lower than the compound 38 concentrations required for producing negatively supercoiled DNA during ligation of nicked 39 circular DNA. Thus, the DNA-binding property of FP-11g may contribute to its 40 antimycobacterial mechanism, but that alone cannot account for the observed inhibition of Mtb 41 topoisomerase I. 42 43 157 Enzyme assays 158

show abstract

Section: Discussionmentioning

confidence: 99%

Mechanism and resistance for antimycobacterial activity of a fluoroquinophenoxazine compound

Garcia

Annamalai

Wang

et al. 2018

Preprint

View full text Add to dashboard Cite

show abstract

“…The full texts of the remaining 38 records were read in full; 19 articles were excluded-seven because of the absence of a control group, one because of the small sample size (<6 NTM-positive patients), and 11 because of the lack of data on risk factors. A total of 19 studies 5,12,19,20,[24][25][26][27][28][29][30][31][32][33][34][35][36][37][38] were finally included (Figure 1), totaling 23 418 patients, of whom 1421 (6%) patients were diagnosed as NTM positive.…”

Section: Study Selectionmentioning

confidence: 99%

“…Ten studies were conducted in Europe, 19,25,[27][28][29][30]32,33,35,37 seven in North America 5,12,24,26,34,36,38 and two in the Middle East 3,20 ( Table 1). Among the seven case-control studies, five were matched on age and sex, 19,24,27,29,32 one on respiratory function, 39 and one on cystic fibrosis transmembrane conductance regulator (CFTR) mutation. 19 Thirteen studies included consecutive patients, and four studies were prospective.…”

Section: Description Of the Studiesmentioning

confidence: 99%

Risk factors for nontuberculous mycobacterial isolation in patients with cystic fibrosis: A meta‐analysis

Reynaud

Bricca

Cavalli

et al. 2020

Pediatric Pulmonology

Self Cite

View full text Add to dashboard Cite

Background To better understand the mechanisms of infection with nontuberculous mycobacteria (NTM) in patients with cystic fibrosis (CF), we explore different risk factors associated with NTM positivity in a meta‐analysis. Methods Studies published before 31 July 2019 were selected from MEDLINE. Combined odds ratios (ORs) were calculated by pooling the ORs of each study. The weighted mean difference (WMD) was used for continuous numerical measurements. Summary data were pooled using fixed‐ or random‐effects models according to the presence of heterogeneity (P < .1 or I2 > 50%). Results Nineteen studies with a total of 23 418 patients, of whom 1421 (6%) were diagnosed as NTM positive, were included. Older age was significantly associated with NTM positivity (WMD = 2.12, 95% confidence interval [CI]: 1.11‐3.13; P < .01, fixed‐effects model). The OR for Staphylococcus aureus colonization was 1.66 (95% CI: 1.21‐2.26; P = .001) in 11 studies (8091 patients), the OR for Aspergillus fumigatus colonization was 3.59 (95% CI: 3.05‐4.23; P < .001) in 11 studies (20 480 patients), and the OR for Stenotrophomonas maltophilia colonization was 3.41 (95% CI: 2.66‐4.39; P < .01) in seven studies (14 935 patients). Oral corticosteroids were significantly associated with NTM positivity (OR = 1.98, 95% CI: 1.24‐3.16; P < .01, 6 studies, 1936 patients). No other factor showed a significant association. Conclusion Older age, S. aureus, S. maltophilia, and A. fumigatus chronic colonization, and oral corticosteroids were significantly associated with an increased risk of NTM positivity. CF patients with more severe conditions should be closely monitored for NTM.

show abstract

“…In patients with CF, NTM sputum positivity has increased from 1.3% in 1984 to 13% in 2017 [19]. Patients with NTM suffer from a more rapid decline in pulmonary function than control patients without NTM although coinfections with SA and Aspergillus may be to blame [20]. Compared to Mycobacterium avium complex, Mycobacterium abscessus complex (MABSC) is more difficult to eradicate and more likely to lead to death or lung transplantation [21].…”

Section: Nontuberculous Mycobacteriamentioning

confidence: 99%

Acute and Chronic Infection Management in CF

Allen

Borick

2020

Cystic Fibrosis in Primary Care

View full text Add to dashboard Cite

High incidence of non-tuberculous mycobacteria-positive cultures among adolescent with cystic fibrosis

Abstract: These data highlight the high incidence of NTM-positive cultures among young adolescents with CF.

Cited by 17 publications

References 30 publications

Mechanism and resistance for antimycobacterial activity of a fluoroquinophenoxazine compound

Mechanism and resistance for antimycobacterial activity of a fluoroquinophenoxazine compound

Risk factors for nontuberculous mycobacterial isolation in patients with cystic fibrosis: A meta‐analysis

Acute and Chronic Infection Management in CF

Contact Info

Product

Resources

About